Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02296242 |
| Title | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | BioMed Valley Discoveries, Inc |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| UCLA Medical Center | Los Angeles | California | 90024 | United States | Details | |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | United States | Details | |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | United States | Details | |
| Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | United States | Details | |
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details |